Federal Register of Legislation - Australian Government

Primary content

Determinations/Health as made
This instrument amends the Health Insurance (Section 3C General Medical Services – Botox, Dysport or Xeomin Injection) Determination 2020 to expand the eligibility for the administration of botulinum toxin (Botox, Dysport and Xeomin).
Administered by: Health
Registered 23 Jul 2020
Table of contents.

Commonwealth Coat of Arms of Australia

 

Health Insurance (Section 3C General Medical Services – Botox, Dysport or Xeomin Injection) Amendment Determination 2020

I, Mary Warner, delegate of the Minister for Health, make the following Determination.

Dated               20 July 2020

 

Mary Warner

Acting Assistant Secretary

MBS Policy and Specialist Services Branch

Medical Benefits Division

Health Financing Group

Department of Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                         


Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1— Amendments................................................................................................... 2

 

 


1  Name

                        This instrument is the Health Insurance (Section 3C General Medical Services – Botox, Dysport or Xeomin Injection) Amendment Determination 2020.

2  Commencement

(1)       Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 August 2020

 

                Note:        This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)       Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                        This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4  Schedules

                        Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


 

Schedule 1— Amendments

Health Insurance (Section 3C General Medical Services – Botox, Dysport or Xeomin Injection) Determination 2020

 

Schedule 1

Repeal the table, substitute:

 

Group T11—Botulinum toxin

Column 1 Item

Column 2
Description

Column 3

Fee ($)

18365

Botulinum Toxin Type A Purified Neurotoxin Complex (Botox) or Clostridium Botulinum Type A Toxin‑Haemagglutinin Complex (Dysport) or IncobotulinumtoxinA (Xeomin), injection of, for the treatment of moderate to severe spasticity of the upper limb following an acute event, if:

(a) the patient is at least 18 years of age; and

(b) treatment is provided as:

(i) second line therapy when standard treatment for the condition has failed; or

(ii) an adjunct to physical therapy; and

(c) the patient does not have established severe contracture in the limb that is to be treated; and

(d) the treatment is for all or any of the muscles subserving one functional activity and supplied by one motor nerve, with a maximum of 4 sets of injections for the patient on any one day (with a maximum of 2 sets of injections for each upper limb), including all injections per set; and

(e) for a patient who has received treatment on 2 previous separate occasions—the patient has responded to the treatment

128.75